Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVSQIV
- Development stage
- Phase 1
- Lead developer
- CureVac
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CVSQIV is an investigational second-generation mRNA-based quadrivalent vaccine designed for the prevention of seasonal influenza. Developed through a collaboration between CureVac and GSK, the vaccine utilizes CureVac's optimized mRNA backbone technology to encode hemagglutinin (HA) proteins from four seasonal influenza strains (two Influenza A and two Influenza B strains). The program was initially co-developed, but in July 2024, GSK acquired full global rights for the development, manufacturing, and commercialization of the candidate. CVSQIV has been evaluated in Phase 1 clinical trials to assess its safety, reactogenicity, and immunogenicity in healthy younger and older adults, administered via intramuscular injection.
- Other names
- seasonal quadrivalent influenza mRNA vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on CVSQIV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVSQIV.